Versant Venture Capital Reports Over 1% Dilution in Stake Due to Company Offerings
Summary
Versant Venture Capital's stake in Tempest Therapeutics has been diluted by over 1% due to the company's recent share issuances, highlighting the impact of ongoing capital raises on major institutional investors.
Key Events
-
Institutional Stake Diluted
Versant Venture Capital's aggregate beneficial ownership percentage in Tempest Therapeutics decreased by over one percent.
-
Passive Ownership Change
The reduction in stake is attributed to dilution from the company's recent sales of additional common stock, not an active disposition by Versant.
-
Context for Recent Offerings
This filing provides insight into the impact of Tempest Therapeutics' recent capital raising activities, including private placements and S-3 registrations, on its institutional shareholder base.
Analysis
This Schedule 13D/A filing by Versant Venture Capital updates their beneficial ownership percentage in Tempest Therapeutics, reflecting a decrease of over one percent due to the company's recent dilutive share issuances. This passive reduction in stake provides important context regarding the impact of Tempest Therapeutics' ongoing capital raising efforts, including recent private placements and S-3 registrations, on its institutional shareholders, especially given the company's recent 'going concern' disclosure.
At the time of this filing, TPST was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.4M. The 52-week trading range was $1.50 to $12.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.